MedTrace Logo

Study of [14C]CS0159 in China Healthy Subjects

NCT06098027 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-11-21

No results posted yet for this study

Summary

Study of \[14C\]CS0159 in China Healthy Subjects.

Conditions

Interventions

DRUG

[14C]CS0159

Single oral administration of 4mg \[14C\]CS0159

Sponsors & Collaborators

  • Cascade Pharmaceuticals, Inc

    lead OTHER

Principal Investigators

  • Deng Rong · Cascade Pharmaceuticals, Inc

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-23
Primary Completion
2023-11-02
Completion
2023-11-02

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06098027 on ClinicalTrials.gov